Seroatlas · Human Serome Atlas

LAS2

Lung adenoma susceptibility protein 2

Also known as: C18orf54, LAS2_HUMAN, MGC33382

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IYD9
Gene: LAS2
Ensembl: ENSG00000166845
Chromosome: 18
Canonical length: 372 aa
Protein class: Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Nucleoplasm,Vesicles,Cytosol
Secretome location: Secreted in male reproductive system

OverviewNCBI Gene

Predicted to act upstream of or within negative regulation of cell population proliferation. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

372 residues, UniProt reviewed canonical sequence.

>Q8IYD9|LAS2
     1  MAKSKTKHRL CSQESSVSAL LASCTLSGSN SSNSDGSFHY KDKLYRSASQ ALQAYIDDFD
    61  LGQIYPGAST GKINIDEDFT NMSQFCNYIY KPNNAFENLD HKKHSNFISC RRHTVNDIDS
   121  MSLTTDDLLR LPADGSFSYT YVGPSHRTSK KNKKCRGRLG SLDIEKNPHF QGPYTSMGKD
   181  NFVTPVIRSN INGKQCGDKI ELLILKAKRN LEQCTEELPK SMKKDDSPCS LDKLEADRSW
   241  ENIPVTFKSP VPVNSDDSPQ QTSRAKSAKG VLEDFLNNDN QSCTLSGGKH HGPVEALKQM
   301  LFNLQAVQER FNQNKTTDPK EEIKQVSEDD FSKLQLKESM IPITRSLQKA LHHLSRLRDL
   361  VDDTNGERSP KM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LAS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.65
Highest tissue expression: 16 nTPM

Expression across tissuesHPA

Tissue

testis: 16 nTPM
thymus: 3.2 nTPM
placenta: 2.9 nTPM
lymph node: 2.8 nTPM
tonsil: 2.5 nTPM
spinal cord: 2.4 nTPM

Single-cell type

early spermatids: 112 nCPM
late primary spermatocytes: 92 nCPM
early primary spermatocytes: 48 nCPM
late spermatids: 39 nCPM
extravillous trophoblasts: 36 nCPM
megakaryocytes: 25 nCPM

Immune cell

non-classical monocyte: 1.9 nTPM
T-reg: 0.7 nTPM
basophil: 0.5 nTPM
gdT-cell: 0.4 nTPM
naive B-cell: 0.4 nTPM
intermediate monocyte: 0.3 nTPM

Brain region

white matter: 11 nTPM
basal ganglia: 7.5 nTPM
medulla oblongata: 7.5 nTPM
pons: 7 nTPM
midbrain: 6 nTPM
cerebellum: 5.7 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.16
gnomAD pLI: 0
DepMap mean gene effect: 0.12
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

negative regulation of cell population proliferation

Cellular components

extracellular region

Protein domainsUniProt · Pfam · InterPro

Lung adenoma susceptibility protein 2
Cell Proliferation Regulator
Lung adenoma susceptibility protein 2

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LAS2 as an antibody target. Whether an autoantibody or antibody against LAS2 could matter depends on whether native LAS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LAS2 is annotated as secreted, so native LAS2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label LAS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...